Methods of lowering active TNF-.alpha. levels in mammals using tumor necrosis factor receptor
AssigneeImmunex Corporation
InventorsCindy A. Jacobs, Craig A. Smith
Life of this patent
Estimating the term…
Abstract
A method for treating TNF-dependent inflammatory diseases in a mammal by administering a TNF antagonist, such as soluble TNFR.
Claims6
A method for lowering the levels of active TNF-.alpha. in a mammal in need thereof which comprises administering to said mammal a TNF-lowering amount of a TNF antagonist selected from the group consisting of:
- (a) a TNF receptor comprising the sequence of amino acids 3-163 of SEQ ID NO:1;
- and
- (b) a chimeric antibody comprising a TNF receptor according to (a) fused to the constant domain of an immunoglobulin molecule.
A method for lowering the levels of active TNF-.alpha. in a mammal in need thereof which comprises administering to said mammal a TNF-lowering amount of a TNF receptor comprising the sequence of amino acids 3-163 of SEQ ID NO:1.
A method for lowering the levels of active TNF-.alpha. in a mammal in need thereof which comprises administering to said mammal a TNF-lowering amount of a chimeric antibody comprising a TNF receptor comprising the sequence of amino acids 3-163 of SEQ ID NO:1 fused to the constant domain of an immunoglobulin molecule.
A method for lowering the levels of active TNF-.alpha. in a mammal having arthritis, which comprises administering to such mammal a therapeutically effective amount of a TNF-antagonist selected from the group consisting of:
- (a) a TNF receptor comprising the sequence of amino acids 3-163 of SEQ ID NO:1;
- and
- (b) a chimeric antibody comprising a TNF receptor according to (a) fused to the constant domain of an immunogloblin molecule.
A method for lowering the levels of active TNF-.alpha. in a mammal having arthritis, which comprises administering to said mammal a TNF-lowering amount of a TNF receptor comprising the sequence of amino acids 3-163 of SEQ ID NO:1.
A method for lowering the levels of active TNF-.alpha. in a mammal having arthritis, which comprises administering to said mammal a TNF-lowering amount of a chimeric antibody comprising a TNF receptor comprising the sequence of amino acids 3-163 of SEQ ID NO:1 fused to the constant domain of an immunoglobulin molecule.
Dependencies are inferred from the claim text.